Presented By: Center for RNA Biomedicine
RNA Seminar: “Translating the cancer genome: dark matter proteins”
John Prensner, MD, PhD, Boston Children's Hospital
In-person/Hybrid seminar co-hosted by The Center for RNA Biomedicine, Department of Computational Medicine & Bioinformatics, and Department of Pediatric Oncology
Talk title: “Translating the cancer genome: dark matter proteins”
Keywords: cancer, ribosome profiling, functional genomics, gene discovery.
Abstract: Although genomic analyses predict many non-canonical open reading frames (ORFs) in the human genome, it is unclear whether they encode biologically active proteins in diseases such as cancer. Here, we have developed functional genomics platforms to systematically interrogate non-canonical ORFs identified in ribosome profiling data. Using CRISPR loss-of-function screens in numerous human cancer models, we define the frequency with which ORFs contribute to cell essentiality phenotypes. We further constructed large-scale ORF plasmid libraries to assess their capacity to encode a protein and induce cancer cell transcriptional changes. We pursued focused investigation of several uncharacterized protein-coding loci, defining roles for the lncRNA-ORF GREP1 in breast cancer and the ASNSD1 upstream ORF (uORF) in medulloblastoma. Lastly, we have assembled a pathway to bring such ORF candidates into the mainstream of biological research via an international consortium of gene database stakeholders. Together, this work establishes non-canonical ORFs as critical mediators of cancer cell biology, suggests their potential promise as therapeutic targets in cancer, and outlines a path forward for dissemination of these ORFs amongst the global research community.
If you are having trouble registering, please contact Martina Jerant at mjerant@umich.edu
Talk title: “Translating the cancer genome: dark matter proteins”
Keywords: cancer, ribosome profiling, functional genomics, gene discovery.
Abstract: Although genomic analyses predict many non-canonical open reading frames (ORFs) in the human genome, it is unclear whether they encode biologically active proteins in diseases such as cancer. Here, we have developed functional genomics platforms to systematically interrogate non-canonical ORFs identified in ribosome profiling data. Using CRISPR loss-of-function screens in numerous human cancer models, we define the frequency with which ORFs contribute to cell essentiality phenotypes. We further constructed large-scale ORF plasmid libraries to assess their capacity to encode a protein and induce cancer cell transcriptional changes. We pursued focused investigation of several uncharacterized protein-coding loci, defining roles for the lncRNA-ORF GREP1 in breast cancer and the ASNSD1 upstream ORF (uORF) in medulloblastoma. Lastly, we have assembled a pathway to bring such ORF candidates into the mainstream of biological research via an international consortium of gene database stakeholders. Together, this work establishes non-canonical ORFs as critical mediators of cancer cell biology, suggests their potential promise as therapeutic targets in cancer, and outlines a path forward for dissemination of these ORFs amongst the global research community.
If you are having trouble registering, please contact Martina Jerant at mjerant@umich.edu